B+
Bull case
30%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
SOLV
SolventumBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$95.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+68.2
Score
AI commentary
News tone is positive following the Q2 results, guidance increase, and HIS separation announcement. The $82.96 adjusted close on August 6 and approximately $82.98 finance quote on August 7 imply essentially flat next-day movement, but a clean pre-release comparison and market attribution are unavailable. No post-print analyst revision signal was found, so confidence remains tentative.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-05eventQ2 2026 results and FY2026 guidance increaseMedium impact
Solventum's official Q2 release reported $2.209 billion of sales, 9.5% organic growth, $2.55 adjusted EPS, and higher FY2026 organic-growth, adjusted-EPS, and free-cash-flow guidance. The SEC filing confirms the release was furnished as Exhibit 99.1. [#IR-2026-08-05] [#SEC-8K-2026-08-05]
2026-08-15catalystPost-earnings guidance resetMedium impact
Q2 organic sales growth of 9.5%, adjusted EPS growth of 50.9%, and higher FY2026 EPS and free-cash-flow guidance support near-term positive momentum, although post-print analyst revisions remain unavailable. [#IR-2026-08-05]
2027-08-08catalystHealth Information Systems separationHigh impact
Management announced its intent to separate Health Information Systems to create a more focused MedTech company; strategic benefits are plausible, but execution and completion timing remain undisclosed. [#IR-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology